Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Inivata Ltd Company Overview 5
Inivata Ltd Company Snapshot 5
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Inivata Ltd – Pipeline Analysis Overview 8
Inivata Ltd – Key Facts 8
Inivata Ltd – Major Products and Services 9
Inivata Ltd Pipeline Products by Development Stage 10
Inivata Ltd Ongoing Clinical Trials by Trial Status 12
Inivata Ltd Pipeline Products Overview 14
InVision ctDNA Assay – EGFR-Mutant NSCLC 14
InVision ctDNA Assay – EGFR-Mutant NSCLC Product Overview 14
InVision ctDNA Assay – Metastatic Breast Cancer 15
InVision ctDNA Assay – Metastatic Breast Cancer Product Overview 15
InVision ctDNA Assay – NSCLC 16
InVision ctDNA Assay – NSCLC Product Overview 16
InVision ctDNA Assay – NSCLC Clinical Trial 17
InVision ctDNA Assay – Pancreatic Cancer 18
InVision ctDNA Assay – Pancreatic Cancer Product Overview 18
InVision ctDNA Assay – Stage III/IV NSCLC 19
InVision ctDNA Assay – Stage III/IV NSCLC Product Overview 19
InVision First 20
InVision First Product Overview 20
InVision First Clinical Trial 21
Inivata Ltd – Key Competitors 22
Inivata Ltd – Key Employees 23
Inivata Ltd – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Inivata Ltd, Recent Developments 25
Oct 26, 2017: Inivata Announces World-Leading SAB 25
Oct 17, 2017: Inivata Highlights New Clinical Data on InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 26
Oct 17, 2017: Inivata Highlights New Clinical Data on InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at WCLC 2017 26
Sep 27, 2017: Addario Lung Cancer Medical Research Institute and Inivata Announce Major Study of ctDNA Analysis in Early Stage Lung Cancer 27
Sep 08, 2017: Inivata Announces Appointment of Dr Jamie Platt as Chief Operations Officer 27
Sep 07, 2017: Inivata: Announces Strategic Partnership with Levine Cancer Institute and Formation of the Inivata Knowledge Accumulation Network 28
Jun 01, 2017: Inivata Highlights New Clinical Data on the InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at ASCO 2017 Annual Meeting 28
Jun 01, 2017: Inivata Highlights New Clinical Data on the InVision ctDNA Liquid Biopsy Platform in advanced NSCLC at ASCO 2017 Annual Meeting 29
May 26, 2017: Inivata, in Collaboration with World-Leading Academic Centers, to Present Promising New Clinical Data on the Utility of the InVision ctDNA Platform across Multiple Tumor Types at ASCO 2017 Annual Meeting 29
Mar 30, 2017: Inivata and Gustave Roussy Publish Positive Results from Prospective Clinical Study in use of ctDNA Liquid Biopsy to Guide Cancer Treatment 30
Appendix 32
Methodology 32
About GlobalData 34
Contact Us 34
Disclaimer 35
Inivata Ltd Pipeline Products and Ongoing Clinical Trials Overview 5
Inivata Ltd Pipeline Products by Equipment Type 6
Inivata Ltd Pipeline Products by Indication 7
Inivata Ltd Ongoing Clinical Trials by Trial Status 7
Inivata Ltd, Key Facts 8
Inivata Ltd, Major Products and Services 9
Inivata Ltd Number of Pipeline Products by Development Stage 10
Inivata Ltd Pipeline Products Summary by Development Stage 11
Inivata Ltd Ongoing Clinical Trials by Trial Status 12
Inivata Ltd Ongoing Clinical Trials Summary 13
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Status 14
InVision ctDNA Assay - EGFR-Mutant NSCLC - Product Description 14
InVision ctDNA Assay - Metastatic Breast Cancer - Product Status 15
InVision ctDNA Assay - Metastatic Breast Cancer - Product Description 15
InVision ctDNA Assay - NSCLC - Product Status 16
InVision ctDNA Assay - NSCLC - Product Description 16
InVision ctDNA Assay - NSCLC - Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation: LIBERTI 17
InVision ctDNA Assay - Pancreatic Cancer - Product Status 18
InVision ctDNA Assay - Pancreatic Cancer - Product Description 18
InVision ctDNA Assay - Stage III/IV NSCLC - Product Status 19
InVision ctDNA Assay - Stage III/IV NSCLC - Product Description 19
InVision First - Product Status 20
InVision First - Product Description 20
InVision First - Evaluation of Liquid Biopsies for Molecular Profiling in Patients with Advanced Non-small Cell Lung Cancer (NSCLC) in the Relapse Treatment Setting 21
InVision First - Prospective Observational Study to Evaluate the Performance of Inivata Liquid Biopsy Analysis Compared with Standard Tissue Biopsy Analysis for Detection of Genomic Alterations in Patients with Advanced Non-small Cell Lung Cancer 21
Inivata Ltd, Key Employees 23
Inivata Ltd, Subsidiaries 24
Glossary 33